-
Figure 1. Neutralization of antibody 2-25 for both IgG and Fab formats based on inhibition of AD169rev-GFP infection in ARPE-19 cells.
| Description | The human antibody specifically recognizes the HCMV pentamer that composes of gH, gL, UL128, UL130, and UL131A. It binds to the junction between ULs 128 and 131A. It exhibits high neutralization potency against HCMV in this post-attachment assay. This product has been determined by Surface plasmon resonance, Bio-layer interferometry and Neutralization assay. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human cytomegalovirus (HCMV) |
| Epitope | Junction between ULs 128 and 131A |
| Neutralization Mechanism | The antibody potently neutralizes HCMV without disrupting NRP2 binding. |
| IC50 | 6.9 pM |
| Affinity | KD = 1.08 nM |
| Isotype | IgG |
| Expression Species | HEK293F or CHO cell |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | SPR; BLI; Neut |
| Application Notes | Surface plasmon resonance (SPR): The affinity of antibody for HCMV Pentamer was determined to be 1.08 nM. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | HCMV Pentamer |
| Alternative Name | Human cytomegalovirus pentamer; HCMV pentamer; gH; gL; UL128; UL130; UL131A |
| Research Area | Infectious Disease |
| Related Disease | Hepatitis, Encephalitis |
Figure 1. Neutralization of antibody 2-25 for both IgG and Fab formats based on inhibition of AD169rev-GFP infection in ARPE-19 cells.
The antibody has potent neutralizing ability against HCMV.
Figure 1. Neutralization of antibody 2-25 for both IgG and Fab formats based on inhibition of AD169rev-GFP infection in ARPE-19 cells.
